Olaparib–capivasertib combination shows promise in solid tumors

Researchers from the Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust (both London, UK) have released results from the first clinical trial to use olaparib in combination with capivasertib. The early-stage trial demonstrated that the novel drug combination was effective against a variety of advanced cancers. Johann de Bono, study leader at the ICR, commented: “Our study establishes the potential of a combination of two precision medicines for patients whose tumors have stopped responding to existing drugs. The combination of olaparib and capivasertib works by attacking two fundamental weaknesses in cancer and could potentially be used...